Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations
Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
India sales grew 23.5% YoY with consolidation of Wockhardt products
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
Subscribe To Our Newsletter & Stay Updated
